FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?

Annals of Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

Abstract [ 18 F]FDG PET/CT is the most widely used PET radiopharmaceutical in oncology, but it not exempt of diagnostic limitations. FAPI have emerged as a great tool management several different solid tumours which able to provide enough information. The aim this work was evaluate available evidence on and therapeutic applications with radiopharmaceuticals. We underwent non-systematic review focusing utility radiopharmaceuticals diagnosis treatment malignancies. present characteristics that can potentially overcome some known limitations F]FDG. high target-to-background ratio (TBR) many such oesophageal cancer, gastric pancreatic hepatic colorectal breast ovarian, cervical head neck cancer. Available suggests TBR improves sensitivity specificity compared F]FDG, especially for detection lymphadenopathies peritoneal metastases, may improve patient radiation planning. Moreover, important underline potential theranostic application

Language: Английский

Superiority of 68Ga-DOTA-FAPI-04 PET/CT to 18F-FDG PET/CT in the evaluation of different cancers with bone metastases

Bone, Journal Year: 2025, Volume and Issue: unknown, P. 117426 - 117426

Published: March 1, 2025

Language: Английский

Comparison of 18F-FDG and 68Ga-DOTA-IBA in detecting bone metastases: a lesion-basis study

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 14, 2025

Language: Английский